share_log

Berenberg Bank Begins Coverage on Certara (NASDAQ:CERT)

Berenberg Bank Begins Coverage on Certara (NASDAQ:CERT)

貝倫貝格銀行開始在Certara上覆蓋(納斯達克:CERT)
Financial News Live ·  2022/09/11 03:31

Berenberg Bank started coverage on shares of Certara (NASDAQ:CERT – Get Rating) in a report released on Thursday, The Fly reports. The firm issued a buy rating and a $23.00 target price on the stock.

據The Fly報道,貝倫貝格銀行在週四發佈的一份報告中開始報道Certara(納斯達克:CERT-GET評級)的股票。該公司對該股發佈了買入評級和23.00美元的目標價。

A number of other analysts have also recently weighed in on CERT. SVB Leerink reduced their target price on shares of Certara from $29.00 to $26.00 and set an outperform rating for the company in a report on Wednesday, August 10th. Credit Suisse Group initiated coverage on shares of Certara in a report on Wednesday, August 24th. They set an outperform rating and a $22.00 target price for the company. Barclays reduced their target price on shares of Certara from $24.00 to $21.00 and set an overweight rating for the company in a report on Wednesday, August 17th. Piper Sandler reduced their target price on shares of Certara from $28.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, August 10th. Finally, Morgan Stanley reduced their target price on shares of Certara from $24.00 to $20.00 and set an equal weight rating for the company in a report on Wednesday, August 24th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of Moderate Buy and an average target price of $26.13.

其他一些分析師最近也對CERT發表了看法。SVB Leerink在8月10日週三的一份報告中將Certara的股票目標價從29.00美元下調至26.00美元,併為該公司設定了表現優於大盤的評級。瑞士信貸集團在8月24日星期三的一份報告中啟動了對Certara股票的報道。他們為該公司設定了跑贏大盤的評級和22.00美元的目標價。巴克萊在8月17日週三的一份報告中將Certara的股票目標價從24.00美元下調至21.00美元,併為該公司設定了增持評級。派珀·桑德勒在8月10日週三的一份報告中將Certara的股票目標價從28.00美元下調至25.00美元,併為該公司設定了增持評級。最後,摩根士丹利在8月24日(週三)的一份報告中將Certara的股票目標價從24.00美元下調至20.00美元,併為該公司設定了同等權重的評級。一名投資分析師對該股的評級為持有,七名分析師對該公司的評級為買入。根據MarketBeat.com的數據,Certara目前的共識評級為中等買入,平均目標價為26.13美元。

Get
到達
Certara
Certara
alerts:
警報:

Certara Price Performance

Certara性價比

CERT opened at $16.28 on Thursday. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -271.33, a price-to-earnings-growth ratio of 1.02 and a beta of 1.27. Certara has a fifty-two week low of $14.94 and a fifty-two week high of $45.48. The company's 50-day moving average price is $19.78 and its 200 day moving average price is $20.07. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.28.

週四,Cert開盤價為16.28美元。該公司市值為26億美元,市盈率為-271.33,市盈率為1.02,貝塔係數為1.27.Certara的價格為52周低點14.94美元和52周高點45.48美元。該公司的50日移動均線價格為19.78美元,200日移動均線價格為20.07美元。該公司的速動比率為3.51,流動比率為3.51,債務權益比率為0.28。

Certara (NASDAQ:CERT – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $82.00 million during the quarter, compared to the consensus estimate of $85.46 million. Certara had a negative net margin of 3.14% and a positive return on equity of 4.26%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share. As a group, sell-side analysts expect that Certara will post 0.28 earnings per share for the current year.
賽達拉(納斯達克:CERT-GET Rating)上一次公佈季度收益數據是在8月9日(星期二)。該公司公佈本季度每股收益(EPS)為0.09美元,低於普遍預期的0.11美元(0.02美元)。該公司本季度營收為8200萬美元,而市場普遍預期為8546萬美元。Certara的淨利潤率為負3.14%,股本回報率為正4.26%。該公司的收入同比增長了17.0%。去年同一季度,該業務每股收益為0.03美元。賣方分析師預計,Certara作為一個整體,本年度每股收益將達到0.28美元。

Insiders Place Their Bets

內部人士下注

In other Certara news, Director Stephen M. Mclean purchased 20,000 shares of the business's stock in a transaction dated Friday, August 19th. The shares were acquired at an average price of $16.32 per share, for a total transaction of $326,400.00. Following the acquisition, the director now owns 42,000 shares of the company's stock, valued at $685,440. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Certara news, CFO Michael Andrew Schemick acquired 25,000 shares of Certara stock in a transaction dated Wednesday, August 17th. The stock was bought at an average cost of $16.64 per share, with a total value of $416,000.00. Following the acquisition, the chief financial officer now owns 517,870 shares of the company's stock, valued at $8,617,356.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen M. Mclean acquired 20,000 shares of Certara stock in a transaction dated Friday, August 19th. The shares were acquired at an average cost of $16.32 per share, with a total value of $326,400.00. Following the completion of the acquisition, the director now directly owns 42,000 shares in the company, valued at approximately $685,440. The disclosure for this purchase can be found here. Insiders sold a total of 6,196,893 shares of company stock worth $107,705,300 in the last quarter. 4.02% of the stock is currently owned by corporate insiders.

在Certara的其他新聞中,董事斯蒂芬·M·麥克萊恩在一筆日期為8月19日(星期五)的交易中購買了20,000股該公司的股票。這些股票是以每股16.32美元的平均價格收購的,總交易額為326,400.00美元。收購完成後,董事現在擁有42,000股該公司股票,價值685,440美元。此次收購是在提交給美國證券交易委員會(Securities&Exchange Commission)的一份文件中披露的,可以通過這個超級鏈接訪問。在Certara的其他新聞中,首席財務官Michael Andrew Schemick在一筆日期為8月17日星期三的交易中收購了Certara股票25,000股。這隻股票的平均價格為每股16.64美元,總價值為416,000.00美元。收購完成後,這位首席財務官現在擁有517,870股公司股票,價值8,617,356.80美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可以通過這個超級鏈接獲得。此外,在8月19日星期五的一筆交易中,董事斯蒂芬·M·麥克萊恩收購了20,000股Certara股票。這些股票是以每股16.32美元的平均成本收購的,總價值為326,400.00美元。收購完成後,董事現在直接擁有該公司42,000股,價值約685,440美元。此次收購的披露信息可在此處找到。上個季度,內部人士總共出售了6,196,893股公司股票,價值107,705,300美元。4.02%的股份目前由企業內部人士持有。

Hedge Funds Weigh In On Certara

對衝基金入股Certara

Institutional investors have recently added to or reduced their stakes in the company. EQT Fund Management S.a r.l. bought a new position in shares of Certara in the second quarter worth about $771,679,000. Clearbridge Investments LLC grew its position in shares of Certara by 58.7% during the 1st quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company's stock worth $68,755,000 after buying an additional 1,183,859 shares during the period. William Blair Investment Management LLC grew its position in shares of Certara by 23.0% during the 4th quarter. William Blair Investment Management LLC now owns 5,540,678 shares of the company's stock worth $157,466,000 after buying an additional 1,034,482 shares during the period. Granite Investment Partners LLC acquired a new position in Certara during the second quarter valued at approximately $18,944,000. Finally, Capital World Investors grew its holdings in Certara by 215.5% during the fourth quarter. Capital World Investors now owns 1,254,554 shares of the company's stock valued at $35,654,000 after purchasing an additional 856,959 shares during the period. 77.42% of the stock is owned by institutional investors.

機構投資者最近增持或減持了該公司的股份。EQT基金管理公司S.A.R.L.在第二季度購買了Certara的新股票頭寸,價值約771,679,000美元。ClearBridge Investments LLC在第一季度將其在Certara股票的頭寸增加了58.7%。ClearBridge Investments LLC現在擁有該公司3,200,895股股票,價值68,755,000美元,在此期間又購買了1,183,859股。威廉·布萊爾投資管理公司在第四季度將其在Certara股票的頭寸增加了23.0%。威廉·布萊爾投資管理公司在此期間又購買了1,034,482股,現在擁有5,540,678股該公司股票,價值157,466,000美元。Granite Investment Partners LLC在第二季度收購了Certara的一個新頭寸,價值約為18,944,000美元。最後,Capital World Investors在第四季度增持了Certara的股份215.5%。Capital World Investors現在持有該公司1,254,554股股票,價值35,654,000美元,在此期間又購買了856,959股。77.42%的股份由機構投資者持有。

About Certara

關於Certara

(Get Rating)

(獲取評級)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Certara公司為客户提供軟件產品和技術支持的服務,用於藥物發現、臨牀前和臨牀研究、監管提交和市場準入方面的生物模擬。它使用生物模擬軟件、技術和服務向患者提供藥物,以改變藥物發現和開發。

Further Reading

進一步閲讀

  • Get a free copy of the StockNews.com research report on Certara (CERT)
  • MarketBeat: Week in Review 9/5 – 9/9
  • Prepare For A Record-Setting Quarter For Cyber Security Stocks
  • The Auto Market Is Slowly Recovering, These Stocks May Outperform
  • Is DocuSign On The Verge Of A Major Reversal?
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • 免費獲取StockNews.com關於Certara的研究報告(CERT)
  • MarketBeat:回顧一週9/5-9/9
  • 為網絡安全股創紀錄的季度做準備
  • 汽車市場正在緩慢復甦,這些股票可能表現優異
  • DocuSign是否即將發生重大逆轉?
  • 石油和天然氣股票:投資可再生能源的安全途徑

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.

接受Certara日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Certara和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論